I like the wording here,... keep in mind they probably can't tell us much!

. The major opportunities in front of us are numerous. We continue to aggressively pursue a multi-point strategy that includes potential breakthrough status filings with regulators and strategic partnerships for multiple indications. All this on the heels of recent significant BETonMACE results which produced very encouraging data, particularly in the chronic kidney disease and cognitive decline patient groups. In addition, we uncovered positive surprise findings when apabetalone is combined with the new generation of diabetes drugs – SGLT2 inhibitors – in this CVD patient population. We look forward to providing further updates in the near future and look forward to a very prosperous 2020.”